Dec. 2, 2010 (PR Newswire) --
- Acquisition strengthens SXC's presence in specialty pharmacy -
- Transaction expected to be immediately accretive to earnings per share
LISLE, Il -SXC Health Solutions Corp. ("SXC" or the "Company")
(NASDAQ: SXCI, TSX: SXC), a leading provider of pharmacy benefit
services and healthcare information technology (HCIT) solutions to the
healthcare benefits management industry, announces that it has entered
into a definitive agreement to acquire MedfusionRx, LLC ("MedfusionRx") for a purchase price of $100 million in cash, subject to certain
customary post-closing adjustments, with an additional $5.5 million
subject to the achievement of certain performance targets through the
2012 fiscal year.
MedfusionRx is a leading privately-owned specialty pharmacy provider with
significant expertise in providing clinical services to over 9,000
patients with complex chronic conditions.
"Specialty pharmaceuticals are the fastest growing area in the PBM space
and our clients recognize it as the next critical area of drug spend
management. This acquisition will expand our presence and enhance our
capabilities in the specialty pharmacy market which differentiates us
from our peers in the mid-market PBM sector," said Mark Thierer,
President and CEO of SXC. "Acquiring MedfusionRx increases the size of our specialty operations to approximately $400
million and allows us to better assist our clients and their members in
managing complex conditions, such as cancer, with the most supportive
and cost-effective care. The MedfusionRx management team adds proven specialty industry experience to our Ascend
team and further expands the scale of our platform to capitalize on the
opportunity in this rapidly growing segment of the PBM industry."
MedfusionRx manages approximately $270 million of drug spend annually and has
approximately $11.5 million in trailing twelve month adjusted EBITDA.
In addition, SXC has identified approximately $4-6 million of cost
saving synergies, including the tax benefits of the acquisition,
expected to be realized within 18-24 months of the closing of the
transaction. The acquisition is expected to be $0.08 to $0.10 accretive
to SXC's GAAP earnings per share ("EPS") in 2011. Excluding an
estimated $7 million in deal-related amortization (or $0.07 per share),
the acquisition is expected to generate $0.15 to $0.17 in adjusted EPS
"SXC has emerged as a leader in the PBM market for technology innovation
and flexible client-focused solutions. Our skill and experience in
specialty pharmaceuticals will help enhance the great work SXC has
already done to transform how pharmacy benefits are delivered. Our
clients, as well as our employees, will benefit greatly from SXC's
operational and financial resources, and we believe that our
client-service culture will merge well with SXC's current specialty
offering," said Jeff Vernon, President of MedfusionRx.
Mr. Thierer continued, "MedfusionRx has a talented team that has expanded its reach into all 50 states.
Importantly, MedfusionRx provides services to more than 30 state clients and manages thousands
of state Medicaid patients, creating some compelling revenue synergy
opportunities for SXC. We are excited with the growth prospects
inherent in this transaction and will continue to explore other
opportunities to expand our business through acquisitions."
MedfusionRx is based in Birmingham, Alabama, where its operations will remain.
Following the closing of the transaction, SXC plans to maintain the MedfusionRx brand. MedfusionRx specializes in the needs of patients across a variety of disease
indications including: bleeding disorders, such as hemophilia; growth
hormone deficiency; multiple sclerosis; rheumatoid arthritis; plaque
psoriasis; Crohn's disease; hepatitis C; oncology; and preventative
treatment of respiratory syncytial virus.
The acquisition is subject to various closing conditions, including the
expiration or termination of the applicable waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act. The transaction is
expected to be completed by the end of 2010.
In connection with the transaction, Healthcare Growth Partners, LLC is
acting as financial advisor and Sidley Austin LLP is acting as legal
counsel to SXC.